

#### Beyond Animal Testing: Development of Organs-on-Chips to Emulate Human Biology

Lorna Ewart, PhD Executive VP European Scientific Liaison

#### **Our Past and Present**


# WYSS S INSTITUTE for Biologically Inspired Engineering








# Organ-Chips: Beyond Animal Models






#### A Window into Human Biology


Organ-Chips provide a window into complex mechanisms of human biology and disease in a way that is not possible with other technologies or animal models

#### Recreating the Cellular Microenvironment in Our Chips

- Extracellular matrix and cell interactions
- Cell shape and cytoarchitecture
- Tissue-tissue interactions
- Mechanical forces
- Dynamic system flow
- Resident or circulating immune cells









Lung-Chip video link: https://vimeo.com/267637620

## LUNG-CHIP





#### Lung inflammation





#### Inflammation and Immune System Interaction in Lung-Chip: Recapitulating Biological Complexity





## LIVER-CHIP






Emulate, Inc.

Science Franslational Veder 209

AAAS

(3) emulate

#### Liver-Chip: Building Tissue Complexity




🛞 emulate

Emulate, Inc.


#### Liver-Chip Developed and Validated with Multiple Partners

- **Co-culture (Hepatocyte + Liver Sinusoidal Endothelial cells)**
- Tri-culture (Hepatocyte + Liver Sinusoidal Endothelial cells, Kupffer)
- Quadruple-culture (Hepatocyte + Liver Sinusoidal Endothelial cells, Kupffer, Stellate cells)





## Liver-Chip: Morphology




Hepatocytes in three species Liver-Chips maintained their stereotypical *in vivo*-like morphologies and formed improved bile canalicular networks compared to plate sandwich culture over 2 weeks in culture



## Liver-Chip: Morphology

Day 14 in culture




Liver-Chip

Characteristic branched bile canalicular networks in hepatocytes over 2 weeks in culture in the Liver-Chips. Expression of the multifunctional scavenger receptor stabilin-1, which is expressed selectively on sinusoidal endothelial cells and is critical for hepatic clearance in LSECs in the Liver-Chips.




#### Liver-Chip: Albumin and Urea Secretions



Human, Rat and Dog Liver-Chips maintain high level of albumin and urea secretions over 2 weeks in culture



#### Liver-Chip: CYP450 Enzyme Activities



Unit : pmol/min/10<sup>6</sup> cells \* p<0.1, \*\* p<0.01, \*\*\* p<0.001, \*\*\*\* p<0.0001

Demonstrated CYP1A, 2B, and 3A activity maintained over 2 week culture



## Liver-Chip: CYP450 Induction for Drug-Drug Interactions

Use of prototypical inducers to evaluate the induction potential by measuring CYP450 enzyme activity and gene expression

#### Selected compounds


- CYP1A inducer: Omeprazole, 50µM
- CYP3A inducer: Rifampicin, 10µM
- CYP2B inducer: Phenobarbital, 1mM

#### Model

- Co-culture Liver-Chip
- Plate

#### Read-out

- CYP450 enzyme activity
- · Gene expression



CYP1A2 induction using omeprazole, activity through acetaminophen CYP2B6 induction using phenobarbital, activity through 4-hydroxycyclophosphamide

Successfully showed ability to induce CYP1A2, CYP2B6, and CYP3A4 enzymes after treatment with prototypical CYP450 inducers in human Liver-Chips




### Predicting Species Differences and MOA in Liver Toxicity


Effect of Bosentan on Albumin Secretion

#### Inhibition of BSEP Transporter

Bos 30µM




Demonstrated species differences in the hepatotoxicity at *in vivo* relevant doses of Bosentan. Albumin data shows dose response effects for dog and human, but not for rat, which correlates with *in vivo data:* human > dog > rat Cholyl-lysyl-fluorescein (CLF) BSEP substrate






#### Predicting Human Safety Risks with Liver-Chip

Compound F caused unexpected toxicity in clinical trial leading to death patients from liver failure. Toxicity not predicted in preclinical animal safety studies






#### Predicting Human Safety Risks with Liver-Chip



Liver-Chip predicted human liver toxicity of compound F observed in clinical trial and provided additional mechanistic data




Liver-Chip: Stellate Cell Activation and Species Difference in Toxicity



Rat Liver-Chip data correlated with rat in vivo data




#### Liver-Chip Predicted Toxicity Observed in Phase III Clinical Trial



Able to measure multiple functional outputs. Richness of the data enabled understanding of the complex biology driving the toxicity




#### Liver-Chip Predicted Toxicity Observed in Phase III Clinical Trial



Key mechanisms of action driving liver toxicity in vivo recapitulated in the Liver-Chip

Liver-Chip predicted toxicity of drug that failed at Phase III clinical trials not predicted in preclinical animal safety studies






Treatment with Comp N caused significant release of the inflammatory cytokines MCP-1 and IL-6 at 10 µM but not at 30 µM; due to overt cell loss / death at higher concentration



# Democratization of the Technology







Emulate, Inc.





Emulate, Inc.





Driving Adoption and Impact on 3Rs: Data, Collaboration, and Partnerships Industry, Government, Academia

#### FDA Collaboration: CRADA



FDA Commissioner talks about Emulate's Organon-Chips platform in his address to the 2017 Science Forum.



"FDA recently signed a research and development agreement with Emulate to explore groundbreaking approaches for toxicity evaluation – using human organ systems in miniature, micro-engineered chips – to study the potentially harmful chemical and biological hazards in foods, dietary supplements, and cosmetics."

Dr. Gottlieb's Remarks to the 2017 FDA Science Forum May 31, 2017

Link to a transcript of FDA Commissioner's Remarks https://www.fda.gov/NewsEvents/Speeches/ucm561256.htm



FDA Signs Collaborative Agreement with Emulate, Inc. to Use Organs-on-Chips Technology as a Toxicology Testing Platform for Understanding How Products Affect Human Health and Safety

Cooperative Research and Development Agreement (CRADA) to advance and qualify 'Human Emulation System' to meet regulatory evaluation criteria for product testing

Link to Official Press Release

https://emulatebio.com/press/fda-collab-agreement-emulate/



Tiny 'Organ Chips' Promise Big Boost to Testing of Food, Drugs Tiny replicas of organs could help doctors and scientists learn about how certain foods, chemicals, and dietary supplements affect the human body,

the Food and Drug Administration (FDA) says.

#### **Blog from FDA**

'Organs-on-Chips' Technology: FDA Testing Groundbreaking Science

Link to FDA Blog

https://blogs.fda.gov/fdavoice/index.php/2017/04/organs-on-chips-technology-fdatesting-groundbreaking-science/









Emulate, Inc.

CONFIDENTIAL INFORMATION